Novo Nordisk's Rybelsus has become the first oral GLP-1 agonist to pick up a regulatory approval for cardiovascular risk reduction, after getting a green light from the EMA's human medicine committee.
AstraZeneca has been cleared to include cardiovascular and kidney outcomes data on the label of its type 2 diabetes therapy Forxiga in the EU which could help it challenge rival drugs in the SGLT2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback